This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Quinine in severe infection of P. falciparum

Authoring team

Seek expert help.

Used as the first line antimalarial drug in the treatment of severe infection in UK (1).

If the patient has a severe infection with P. falciparum (or unknown species) then:

Treat with quinine dihydrochloride (adult regime):

  • loading dose: 20mg/kg quinine dihydrochloride in 5% dextrose or dextrose saline. This is given over 4 hours by i.v. infusion - then after 8 hours maintenance dose is given
  • maintenance dose: 10 mg/kg given over 4 hours by i.v. infusion 8hourly for first 48 hours (or until patient can swallow oral medication)
  • in case of i.v. quinine continuing for more than 48 hours frequency of the dosing should be reduced to 12 hours
  • a substitute loading dose regimen for adults are: 7 mg/kg quinine dihydrochloride over 30 min with an infusion pump followed by the maintenance dose
  • when the patient is well enough to take oral medication, oral quinine should be substituted (600 mg 3 times a day) to complete a total course of 5-7 days and doxycycline 200 mg daily (or clindamycin 450 mg 3 times a day for pregnant women) should also be given for a total of 7 days

The respective summary of product characteristics must be consulted before prescribing the drugs mentioned.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.